Optische Kohärenztomographie zur Beurteilung von Uveitis im Mausmodell

Executive Industry Relevance

Optical coherence tomography (OCT) enables non-invasive, longitudinal assessment of ocular inflammation in preclinical models, supporting target validation and mechanistic de-risking in ophthalmic drug development. By quantifying immune cell infiltration and tissue edema, OCT provides predictive readouts that improve go/no-go decisions and reduce late-stage failure risk in uveitis therapeutics. This imaging approach bridges discovery biology and translational research through objective, reproducible inflammation scoring.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by visualizing immune cell infiltration in ocular tissues.
• Operational Value: Supports functional target validation through longitudinal tracking of inflammation dynamics.
• Predictive Value: Enhances portfolio triage by correlating imaging readouts with disease severity and treatment response.

Screening & Assay Development

• Assay Readiness: Prepares validated biological systems for compound evaluation via standardized inflammation scoring.
• Reproducibility: Ensures consistent quantitative outputs across sessions through standardized OCT acquisition protocols.
• Scalability: Enables high-content screening readiness by generating cross-sectional images suitable for automated analysis.

Translational & Preclinical Research

• Disease Relevance: Models post-infectious uveitis with immune cell infiltration and vascular leakage, reflecting human pathophysiology.
• Translational Continuity: Bridges discovery and preclinical validation by providing quantitative inflammation metrics applicable to therapeutic screening.
• Risk-Adjusted Advancement: Supports go/no-go decisions by linking imaging biomarkers to mechanistic pathways of ocular inflammation.

Pipeline & Workflow Integration

OCT imaging fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing, enabling data-driven decisions at each stage.

• Discovery Biology: Supports hypothesis testing by visualizing immune responses and clarifying inflammatory pathways in the eye.
• Screening: Delivers assay-ready, reproducible quantitative outputs that allow comparison of compound effects on ocular inflammation.
• Analytics: Provides inflammation scoring based on OCT image analysis, enabling teams to quantify severity and track progression.
• Translational Research: Connects to preclinical validation through disease-relevant imaging biomarkers that mirror clinical uveitis assessment.
• Enterprise Reuse: Functions as a reusable imaging platform across multiple ocular disease models and therapeutic modalities.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by reducing mechanistic ambiguity in ocular immune responses.
• Operational Value: Delivers standardization, reproducibility, and scalability in inflammation assessment across studies.
• Strategic Value: Improves go/no-go decisions, enhances capital efficiency, and reduces late-stage biological risk in ophthalmic programs.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement decisions based on quantitative inflammation metrics.

Implementation Considerations

• Requires expertise in ocular anatomy, OCT system operation, and image analysis for inflammation scoring.
• Depends on access to preclinical OCT imaging systems capable of anterior and posterior segment visualization.
• Necessitates cross-team standardization of imaging protocols, pupil dilation procedures, and scoring criteria.
• Involves adaptation considerations across mouse strains, disease models, and ocular pigmentation affecting light penetration.
• Limited by the need for anesthesia and immobilization, which may influence physiological state during imaging.

Biopharma FAQs